Losartan Potassium Drug Interactions
Also known as: Cozaar, Hyzaar (with hydrochlorothiazide)
Losartan potassium (Cozaar) is an angiotensin II receptor blocker (ARB) used to treat high blood pressure, protect the kidneys in type 2 diabetes, and reduce the risk of stroke in patients with hypertension and left ventricular hypertrophy. Unlike ACE inhibitors, losartan does not cause a dry cough and carries a significantly lower risk of angioedema. It is also the only ARB with a clinically meaningful uricosuric (uric acid-lowering) effect, making it a preferred choice in patients with hypertension and gout.Losartan Potassium has 6 documented drug interactions in our database, including 0 contraindicated, 3 major, 3 moderate, and 0 minor interactions.
0
Contraindicated
3
Major
3
Moderate
0
Minor
Dual blockade of the renin-angiotensin system with an ACE inhibitor and ARB increases the risk of hypotension, hyperkalemia, and acute kidney injury.
Mechanism
Both drug classes independently block the RAAS pathway. Combined use provides no additional cardiovascular benefit but doubles the risk of adverse renal and electrolyte effects.
Clinical Management
Avoid combination in most patients. If used, monitor blood pressure, renal function, and potassium closely.
Concurrent use of losartan and spironolactone significantly increases the risk of hyperkalemia (elevated serum potassium). Both drugs reduce potassium excretion through complementary mechanisms — losartan blocks aldosterone secretion via AT1 receptor blockade, while spironolactone directly antagonizes aldosterone receptors in the kidney. The combination can cause life-threatening hyperkalemia, particularly in patients with renal impairment, diabetes, or heart failure.
Mechanism
Losartan reduces angiotensin II-mediated aldosterone secretion from the adrenal cortex (via AT1 receptor blockade), decreasing renal potassium excretion. Spironolactone competitively antagonizes aldosterone at the mineralocorticoid receptor in the collecting duct, further reducing potassium excretion. The additive effect on potassium retention can cause serum potassium to rise to dangerous levels (>6 mEq/L).
Clinical Management
Use with caution; avoid in patients with eGFR <30 mL/min/1.73m² or baseline potassium >5.0 mEq/L. Monitor serum potassium and renal function within 1–2 weeks of initiating the combination and periodically thereafter. Instruct patients to avoid potassium-containing salt substitutes and high-potassium foods. Consider reducing the spironolactone dose or switching to a loop diuretic if hyperkalemia develops. This combination is used intentionally in heart failure (RALES trial) but requires careful monitoring.
Concurrent use of losartan and eplerenone significantly increases the risk of hyperkalemia. Both drugs reduce renal potassium excretion through complementary RAAS-blocking mechanisms. Eplerenone is a selective aldosterone antagonist with a lower risk of hormonal side effects than spironolactone, but the hyperkalemia risk with ARB co-administration is equivalent.
Mechanism
Losartan blocks AT1 receptors, reducing angiotensin II-stimulated aldosterone secretion and thereby decreasing renal potassium excretion. Eplerenone selectively blocks mineralocorticoid receptors in the kidney collecting duct, further reducing potassium excretion. The additive potassium-retaining effect can cause clinically significant hyperkalemia.
Clinical Management
Avoid in patients with eGFR <30 mL/min/1.73m², diabetes with microalbuminuria (eplerenone is contraindicated), or baseline potassium >5.0 mEq/L. Monitor serum potassium and creatinine within 1–2 weeks of initiating the combination and every 3 months thereafter. Reduce eplerenone dose or discontinue if potassium exceeds 5.5 mEq/L. Avoid potassium supplements and salt substitutes.
Naproxen, like all NSAIDs, can reduce the antihypertensive effect of losartan and increase the risk of acute kidney injury. The mechanism and clinical significance are identical to the losartan-ibuprofen interaction. Naproxen has a longer half-life (12–17 hours) than ibuprofen, which may prolong the duration of the interaction.
Mechanism
Naproxen inhibits COX-1 and COX-2, reducing prostaglandin-mediated renal vasodilation and causing sodium/water retention. This directly opposes the antihypertensive and renal-protective effects of losartan. In patients with reduced renal reserve, the combination can precipitate acute kidney injury through the same 'triple whammy' mechanism as ibuprofen.
Clinical Management
Same as for ibuprofen: avoid regular use in patients taking losartan with CKD, heart failure, or concurrent diuretics. If short-term use is necessary, use the lowest effective dose, monitor blood pressure and renal function, and ensure adequate hydration. Consider acetaminophen as a safer alternative for pain management in patients on ARBs.
Concomitant use of ibuprofen and losartan can lead to a decrease in the antihypertensive effect of losartan and an increased risk of renal dysfunction, particularly in elderly, dehydrated, or renally impaired patients. This combination can also increase the risk of hyperkalemia.
Mechanism
Ibuprofen, a nonsteroidal anti-inflammatory drug (NSAID), inhibits prostaglandin synthesis, which can counteract the vasodilator effects of losartan and lead to sodium and water retention. In susceptible patients, this can impair renal perfusion and function when combined with the angiotensin receptor blockade of losartan.
Clinical Management
Monitor blood pressure closely when initiating or discontinuing ibuprofen in patients on losartan. Assess renal function (e.g., serum creatinine, GFR) and serum potassium levels regularly, especially in high-risk patients. Advise patients to maintain adequate hydration.
Losartan can increase serum lithium concentrations, potentially leading to lithium toxicity. ARBs reduce renal lithium clearance by causing sodium depletion and activating compensatory sodium (and lithium) reabsorption in the proximal tubule. Lithium has a narrow therapeutic index (0.6–1.2 mEq/L), and even modest increases in serum levels can cause toxicity.
Mechanism
Losartan reduces aldosterone secretion via AT1 receptor blockade, leading to mild natriuresis. The resulting sodium depletion activates compensatory sodium reabsorption in the proximal tubule via the sodium-lithium countertransporter. Since lithium is handled similarly to sodium in the proximal tubule, its reabsorption increases proportionally, reducing renal lithium clearance and raising serum lithium levels. This mechanism is shared by all ARBs and ACE inhibitors.
Clinical Management
Monitor serum lithium levels more frequently when initiating, adjusting, or discontinuing losartan. Check lithium levels within 1–2 weeks of any change in losartan dose. Educate patients on signs of lithium toxicity: tremor, confusion, nausea, vomiting, ataxia, and polyuria. Consider reducing the lithium dose when adding losartan. Ensure adequate sodium intake and hydration to minimize the natriuretic effect of losartan.
For complete prescribing information:
View full Losartan Potassium monograph →Already managing multiple medications?
Compare prices for all your prescriptions at 67,000+ pharmacies with one free RxGo search.
Medical Disclaimer
The information on RxGuide is intended for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician, pharmacist, or other qualified health provider with any questions you may have regarding a medical condition or medication. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.